Patheon announced today the appointment of Michael E. Lytton
as Patheon's Executive Vice President, Corporate Development and Strategy and
General Counsel, effective immediately. Mr. Lytton was most recently with
Biogen Idec, Inc., where he held the position of Executive Vice President, Corporate
and Business Development reporting to Jim Mullen, previously Chief Executive
Officer of Biogen Idec and now Patheon's Chief Executive Officer.
In commenting on the appointment, Mr. Mullen said, "I
am so pleased that Michael has agreed to join us. He is an accomplished leader,
strategist and negotiator who will bring a deep and broad understanding of the
industry and proven skills to help Patheon reach its full potential. I expect
that Michael will assist us in building strategic alliances with our pharmaceutical
and biotechnology customers as well as emerging companies and their investors,
and that he will enable us to add a range of proprietary capabilities and technologies
to better serve our customers." Mr. Lytton's 28-year career includes
extensive experience in the pharmaceutical and biotech industry. Most recently,
Mr. Lytton supported Biogen Idec's growth by leading its corporate development team
that refined and executed its corporate partnership strategy, including the
in-licensing of several late-stage molecules. Prior to joining Biogen Idec, Mr.
Lytton was a General Partner with Oxford Bioscience Partners, a venture capital
firm investing in therapeutic, diagnostic, and life science tool companies.
Prior to Oxford,
Mr.
Lytton practiced law for 17 years and specialized in
representing biomedical companies; he is a past Partner and member of the
Executive Committee of the law firm Edwards Angell Palmer & Dodge and
previously was a Partner of the law firm Wilmer Hale.
Mr. Lytton is currently Chairman of the Board of Santhera Pharmaceuticals
AG and he has also served on various boards of many other academic, non-profit
and private and public for-profit companies throughout his career.
Mr. Lytton holds an undergraduate degree from Princeton University,
a Master of Science degree in Epidemiology from the London School of Hygiene
and Tropical Medicine at the University of London, U.K. where he was a
Fulbright Scholar, and a Juris Doctor from Harvard Law
School.